1/16
11:51 am
srpt
Sarepta Preliminary Results: Not What The Market Wanted To Hear [Seeking Alpha]
Neutral
Report
Sarepta Preliminary Results: Not What The Market Wanted To Hear [Seeking Alpha]
1/16
09:32 am
srpt
Sarepta Therapeutics: Is Elevidys A Bust? [Seeking Alpha]
Low
Report
Sarepta Therapeutics: Is Elevidys A Bust? [Seeking Alpha]
1/15
05:20 pm
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Royal Bank Of Canada from $16.00 to $18.00. They now have a "sector perform" rating on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Royal Bank Of Canada from $16.00 to $18.00. They now have a "sector perform" rating on the stock.
1/14
08:04 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
1/12
12:05 pm
srpt
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues [Yahoo! Finance]
Low
Report
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues [Yahoo! Finance]
1/12
11:58 am
srpt
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Low
Report
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
1/8
12:22 am
srpt
Assessing Sarepta Therapeutics (SRPT) Valuation After SRP-1005 Huntington's Disease Trial Application [Yahoo! Finance]
Low
Report
Assessing Sarepta Therapeutics (SRPT) Valuation After SRP-1005 Huntington's Disease Trial Application [Yahoo! Finance]
1/7
09:17 am
srpt
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease [Yahoo! Finance]
1/7
08:30 am
srpt
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
Medium
Report
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
1/5
08:30 am
srpt
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/31
05:20 pm
srpt
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/19
08:05 pm
srpt
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory [Yahoo! Finance]
Low
Report
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory [Yahoo! Finance]
12/14
07:56 pm
srpt
A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. [CBS News]
Low
Report
A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. [CBS News]
12/14
07:56 pm
srpt
Breakthrough genetic therapies can save lives, but many cost millions for single dose [CBS News]
Low
Report
Breakthrough genetic therapies can save lives, but many cost millions for single dose [CBS News]
12/11
07:00 am
srpt
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
Low
Report
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
12/10
12:42 am
srpt
Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound [Yahoo! Finance]
Low
Report
Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound [Yahoo! Finance]
12/9
08:19 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.
11/25
08:57 am
srpt
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Low
Report
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
11/24
07:30 am
srpt
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
Medium
Report
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
11/20
10:00 am
srpt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
11/15
11:39 am
srpt
Is Sarepta Therapeutics a Bargain After Its 82% Drop Over the Last Year? [Yahoo! Finance]
Medium
Report
Is Sarepta Therapeutics a Bargain After Its 82% Drop Over the Last Year? [Yahoo! Finance]
11/14
03:22 pm
srpt
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance Canada]
Low
Report
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance Canada]
11/14
03:20 pm
srpt
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance]
Low
Report
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance]
11/14
02:54 pm
srpt
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
Medium
Report
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
11/8
01:17 pm
srpt
Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at
Wall St
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at
Wall St